secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K/A
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001193125-23-003686
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD closes Mayne Pharma license deal, appoints new CEO, reports pro forma loss
--------------------------------------------------------------------------------

- On Dec 30, 2022, terminated co-CEOs Brian Bernick and Mark Glickman; Glickman eligible for $100k consulting fee plus performance bonuses.
- On Jan 4, 2023, appointed General Counsel Marlan Walker as CEO and Principal Executive Officer.
- Mayne Pharma paid $140M upfront for licenses and assets; plus ~$12.1M for working capital and $1M prepaid royalties.
- Pro forma 2021 net loss of $7.0M, 9mo 2022 net loss of $6.6M; balance sheet shows debt eliminated, cash of ~$128M post-transaction.
- Royalty stream includes 8% on first $80M annual sales, minimum $3M/year for 12 years, and milestone payments up to $30M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/0001193125-23-003686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000119312523003686/d389338d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-003686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer